BIOD 531

Drug Profile

BIOD 531

Alternative Names: BIOD-531; Concentrated ultra-rapid-acting insulin - Albireo Pharma

Latest Information Update: 12 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biodel
  • Developer Albireo Pharma
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 09 Mar 2016 Biodel terminates a phase II trial in Type-2 diabetes mellitus in USA due to the withdrawal of IND (NCT02446028)
  • 17 Dec 2015 Biodel suspends a phase IIa trial in Type-2 diabetes mellitus (Combination therapy) in USA (Study 3-157)
  • 03 Nov 2015 Phase-II clinical trials in Type-2 diabetes mellitus (Combination therapy) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top